Aclaris Therapeutics Inc (NASDAQ:ACRS) major shareholder James E. Flynn sold 454,261 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $4.59, for a total transaction of $2,085,057.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
NASDAQ ACRS traded down $0.01 on Thursday, hitting $2.10. 280,876 shares of the company were exchanged, compared to its average volume of 607,114. The stock has a market capitalization of $86.25 million, a P/E ratio of -0.52 and a beta of 0.77. Aclaris Therapeutics Inc has a 12 month low of $1.93 and a 12 month high of $20.75. The stock’s fifty day moving average is $3.69. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.30 and a current ratio of 4.33.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.05). Aclaris Therapeutics had a negative return on equity of 78.05% and a negative net margin of 999.53%. The company had revenue of $5.04 million for the quarter, compared to the consensus estimate of $5.13 million. As a group, research analysts anticipate that Aclaris Therapeutics Inc will post -2.87 earnings per share for the current year.
A number of equities research analysts have recently commented on ACRS shares. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Leerink Swann lowered shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 27th. Zacks Investment Research raised shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Monday, July 8th. Svb Leerink lowered shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $19.69.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Read More: Stock Split
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.